BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, March 21, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 19, 2012
View Archived Issues
New strategy shows promise to eradicate latent HIV-1
Read More
ROCK inhibitor and calcium channel blocker show synergy in phase I trial
Read More
New PI3Kalpha and mTOR inhibitors designed in Spain
Read More
New antibacterial products presented
Read More
Aileron Therapeutics reports new candidate cancer therapies
Read More
Prostaglandin E2 derivative shows therapeutic potential in preclinical and clinical studies
Read More
New PARP-1 inhibitors synthesized in China
Read More
MediVector receives U.S. DOD contract to develop broad-spectrum influenza drug
Read More
SK Biopharmaceuticals launches phase II trial of constipation therapeutic
Read More
Genmab submits protocol amendment for phase III ofatumumab trial
Read More
Pharmaxis provides update on Bronchitol MAA
Read More
Medivir to file application for phase I trials of bone disorder candidate
Read More
NICE issues recommendation for dabigatran
Read More
Wintherix presents new activators of Wnt signaling
Read More
Novel somatostatin sst5 receptor antagonists developed
Read More
Novel E-NPP 2 inhibitors disclosed
Read More
Alcon and Astellas Pharma report new bradykinin receptor agonists
Read More
Boehringer Ingelheim Pharma designs new FLAP and leukotriene synthesis inhibitors
Read More
Novel hedgehog pathway activators divulged by Fate Therapeutics
Read More
FDA grants orphan drug status to verteporfin therapy
Read More
Telormedix completes safety portion of TMX-101 study
Read More
Galderma completes phase III studies of candidate for facial erythema of rosacea
Read More
Health Canada approves diclofenac therapy
Read More
TH-302 receives E.U. orphan drug status
Read More
Sodium channel blocker enters proof-of-concept trial
Read More
FDA proposes adjustment to risk classification of certain tuberculosis tests
Read More
